Really great technology. Though the NALFD is a big problem I am worried that is not quite the right market target. The business case for brain scanning in a small mobile package is very strong but livers can be scanned with conventional equipment and there is no emergency scenario to make the key benefit feature a must have. Maybe a better goal would be liver/organ trauma detection. That portability would provide a compelling purchase driver in POC trauma applications. It would also allow a dual use for a mobile device backbone and increase the development ROI.
Really great technology. Though the NALFD is a big problem I am...
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.93 |
Change
0.040(2.12%) |
Mkt cap ! $174.4M | |||
| Open | High | Low | Value | Volume |
| $1.91 | $1.95 | $1.91 | $140.5K | 72.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2067 | $1.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.93 | 4701 | 1 |
View Market Depth
| Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
| EMV (ASX) Chart |
